Reply to “Exploring the long-term effects of biologic initiation in severe asthma: Insights from the International Severe Asthma Registry”

摘要: REFERENCES 1. Ramiro S, Lukas C, Nissen MJ, Schymura Y, Ng K, Bradley A, et al. Pos0931 efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological naıve patients with radiographic axial spondyloarthritis achieving clinically important pain at night reduction at week 16: results from coast-v trial. Ann Rheum Dis 2022; 81 (Suppl 1): 765-6. 2. Di Sanzo L, Scrivo R, Soriano ER, Citera G, Mysler E, Wei JC-C, et al. Editorial: Drug survival: treatment of rheumatic diseases in the biologic era. Front Med (Lausanne) 2022; 9: 858817.3. Chen W, Tran TN, Sadatsafavi M, Murray R, Wong NCB, Ali N, et al. Impact of initiating biologics in patients with severe asthma on long-term oral corticosteroids or frequent rescue steroids (GLITTER): data from the International Severe Asthma Registry. J Allergy Clin Immunol Pract 2023; 11: 2732-47. 4. Mustafa SS, Patrawala S, Khurana S …